In contrast, previously unreported variants in TP53 (c.772G>A) and <i>NOTCH1</i> (c.7546T>G) were also computationally predicted to be deleterious and were significantly enriched in aggressive subtypes, with ORs of 15.1 (adjusted <i>p</i>-value = 0.01) and 18.4 (adjusted <i>p</i>-value = 0.026), respectively.<h4>Conclusion</h4>These hypothesis-generating findings suggest that variations in <i>GTF2I</i>, <i>TP53</i>, and <i>NOTCH1</i> may serve as candidate molecular markers for distinguishing thymoma subtypes and assessing patient risk. This evidence concerns the gene NOTCH1 and thymoma.